Turn Therapeutics Inc. announced on September 9, 2026, the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer. Dr. Redfield joins the clinical-stage biotechnology company, which is developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.
Dr. Redfield brings more than four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health. He previously served as the 18th Director of the U.S. Centers for Disease Control and Prevention from 2018 to 2021. Prior to his role at the CDC, he was a Professor of Medicine, Microbiology, and Immunology and Chief of Infectious Diseases at the University of Maryland School of Medicine. He also spent approximately two decades in the U.S. Army Medical Corps, retiring with the rank of Colonel.
At Turn Therapeutics, Dr. Redfield will contribute to the scientific and clinical strategy for the company’s lead therapeutic candidate, GX-03. His work will focus on cytokine signaling and the host inflammatory response to microbial stimulus. The company is currently evaluating GX-03 in atopic dermatitis and is also developing the candidate for onychomycosis. Preclinical research has demonstrated effects on inflammatory mediators implicated in atopic dermatitis, including IL-36 and IL-31.
Dr. Redfield will work closely with Bradley Burnam, founder and Chief Executive Officer, and Stephen M. Hahn, M.D., Turn Therapeutics Executive Clinical and Regulatory Lead and former Commissioner of the U.S. Food and Drug Administration.
